{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:18:52Z","timestamp":1792016332027,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,7,6]],"date-time":"2004-07-06T00:00:00Z","timestamp":1089072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1038\/sj.bjc.6602000","type":"journal-article","created":{"date-parts":[[2004,7,7]],"date-time":"2004-07-07T01:36:19Z","timestamp":1089164179000},"page":"627-632","source":"Crossref","is-referenced-by-count":21,"title":["A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer"],"prefix":"10.1038","volume":"91","author":[{"given":"M","family":"Harries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Perren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Everard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"A'Hern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Gibbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Pizzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,7,6]]},"reference":[{"key":"BF6602000_CR1","first-page":"88","volume":"22","author":"DS Alberts","year":"1995","unstructured":"Alberts DS (1995) Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 22: 88\u201390","journal-title":"Semin Oncol"},{"key":"BF6602000_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0169-5002(02)00145-9","volume":"38","author":"S Bhatia","year":"2002","unstructured":"Bhatia S, Hanna N, Ansari R, Pletcher W, Einhorn L, Ng E, Sandler A (2002) A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 38: 73\u201377","journal-title":"Lung Cancer"},{"key":"BF6602000_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2","volume":"92","author":"G Cassinelli","year":"2001","unstructured":"Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F (2001) A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738\u2013747","journal-title":"Int J Cancer"},{"key":"BF6602000_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","volume":"88","author":"G D'Agostino","year":"2003","unstructured":"D'Agostino G, Amant F, Berteloot P, Scambia G, Vergote I (2003) Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88: 266\u2013269","journal-title":"Gynecol Oncol"},{"key":"BF6602000_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1023\/A:1008355317514","volume":"10","author":"A Du Bois","year":"1999","unstructured":"Du Bois A, Neijt JP, Thigpen JT (1999) First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer \u2013 a new standard of care? Ann Oncol 10: 35\u201341","journal-title":"Ann Oncol"},{"key":"BF6602000_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1023\/A:1008469212268","volume":"9","author":"M Friedlander","year":"1998","unstructured":"Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L (1998) A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol 9: 1343\u20131345","journal-title":"Ann Oncol"},{"key":"BF6602000_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sonc.2002.31593","volume":"29","author":"SW Hansen","year":"2002","unstructured":"Hansen SW (2002) Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 29: 17\u201319","journal-title":"Semin Oncol"},{"key":"BF6602000_CR8","unstructured":"Hansen SW, Anderson H, Boman K, Hansen M, Havsteen H, Rosenberg P, S\u00f8rensen PG, Vergote I (1999) Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages II\u2013IV. Pro Am Soc Clin Oncol 18, (abst 1379)"},{"key":"BF6602000_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1470-2045(02)00846-X","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M (2002) Chemotherapy for epithelial ovarian cancer \u2013 Part I. Treatment at first diagnosis. Lancet Oncol 3: 529\u2013536","journal-title":"Lancet Oncol"},{"key":"BF6602000_CR10","doi-asserted-by":"crossref","unstructured":"ICON group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505\u2013515","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"BF6602000_CR11","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","volume":"86","author":"B Lund","year":"1994","unstructured":"Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2\u2032,2\u2032-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530\u20131533","journal-title":"J Natl Cancer Inst"},{"key":"BF6602000_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1\u20136","journal-title":"N Engl J Med"},{"key":"BF6602000_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","volume":"18","author":"FM Muggia","year":"2000","unstructured":"Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18: 106\u2013115","journal-title":"J Clin Oncol"},{"key":"BF6602000_CR14","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21: 3194\u20133200","journal-title":"J Clin Oncol"},{"key":"BF6602000_CR15","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","volume":"361","author":"MK Parmar","year":"2003","unstructured":"Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial. Lancet 361: 2099\u20132106","journal-title":"Lancet"},{"key":"BF6602000_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin\u2013paclitaxel versus cisplatin\u2013cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"BF6602000_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s004320050327","volume":"125","author":"A Sauer-Heilborn","year":"1999","unstructured":"Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K (1999) Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 125: 637\u2013640","journal-title":"J Cancer Res Clin Oncol"},{"key":"BF6602000_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/gyno.1996.0284","volume":"63","author":"JD Shapiro","year":"1996","unstructured":"Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89\u201393","journal-title":"Gynecol Oncol"},{"key":"BF6602000_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00000421-199910000-00005","volume":"22","author":"DF Silver","year":"1999","unstructured":"Silver DF, Piver MS (1999) Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am J Clin Oncol 22: 450\u2013452","journal-title":"Am J Clin Oncol"},{"key":"BF6602000_CR20","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1016\/S0959-8049(00)00341-5","volume":"36","author":"AL Thomas","year":"2000","unstructured":"Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I\/II dose-escalating study. Eur J Cancer 36: 2329\u20132334","journal-title":"Eur J Cancer"},{"key":"BF6602000_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/00001813-200109000-00002","volume":"12","author":"CR Underhill","year":"2001","unstructured":"Underhill CR, Parnis FX, Highley MS, Ahern J, Harper PG, Hansen H, Lund B, Dombernowsky P, Hirsch F, Hansen M, Carmichael J, Williams C (2001) Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs 12: 647\u2013652","journal-title":"Anticancer Drugs"},{"key":"BF6602000_CR22","first-page":"202a","volume":"20","author":"P Vasey","year":"2001","unstructured":"Vasey P (2001) Preliminary results of the SCOTROC II trial: a phase III comparison of paclitaxel\u2013carboplatin (PC) and docetaxel\u2013carboplatin (DC) as first-line chemotherapy for Stage Ic-IV epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 20: 202a (abstract 804)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602000_CR23","first-page":"202a","volume":"21","author":"PA Vasey","year":"2002","unstructured":"Vasey PA (2002) Survival and longer-term toxicity results of the SCOTROC study: docetaxel\u2013carboplatin (DC) vs paclitaxel\u2013carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 21: 202a (abstract 804)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6602000_CR24","unstructured":"Vasey P, Atkinson R, Osborne R, Parkin D, Paul S, Coleman R, Paul J, Lewsley EA, Kaye S, Rustin G (2003) Carboplatin (Cb) followed sequentially by docetaxel (D)+\/\u2212gemcitabine (G) in ovarian, peritoneal and fallopian tube cancers; results of SCOTROC 2A. Proc Am Soc Clin Oncol 22, (abstract 804)"},{"key":"BF6602000_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1023\/A:1008364327684","volume":"10","author":"G Von Minckwitz","year":"1999","unstructured":"Von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP (1999) Phase II study of gemcitabine in ovarian cancer. Ann Oncol 10: 853\u2013855","journal-title":"Ann Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602000","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:10:32Z","timestamp":1684411832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["BF6602000"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602000","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,6]]}}}